• NuWays reiterated a BUY on NanoRepro, raising its 12-month target price to EUR 4.4 from EUR 4.3.
• Preliminary H1 2026 revenue rose 26% to EUR 13 million, ahead of NuWays’ EUR 11 million estimate.
• NuWays lifted its FY 2026 sales forecast to EUR 18.8 million from EUR 17.6 million on stronger-than-expected demand at Paedi Protect.
• Process optimization is expected to support a swing to positive EBITDA by FY 2027; NuWays sees an EBITDA margin of 7%.
• FY 2026 EBITDA is forecast at EUR -0.1 million, versus EUR -1.7 million in FY 2025, reflecting cost actions and higher scale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoRepro AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_26254) on July 22, 2026, and is solely responsible for the information contained therein.